Virginia is currently home to 1824 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MOnaliZumab in Combination with DurvAlumab (MEDI4736) Plus Platinum-based ChemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Recruiting
The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, subjects will continue maintenance treatment with durvalumab plus monalizumab every 4 weeks until disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal of consent. Patients who have received one prior cycle of treatment before enrolling on the study will receive a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer
REBYOTA™ Prospective Registry
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Charlottesville, Virginia
Conditions: Recurrence of Clostridium Difficile Infection
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
Recruiting
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/13/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Nodule Solitary Pulmonary, Non-small Cell Carcinoma
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Recruiting
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Lung Neoplasm
A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
Recruiting
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: Virginia Nephrology Group, Arlington, Virginia
Conditions: Proteinuric Kidney Disease
Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA
Recruiting
The purpose of this research is to collect medical imaging data to allow for the comparison of bone mineral density measurements from two different types of low-dose x-ray exams, EOSedge and conventional DXA. The main question it aims to answer is: Is there agreement between the calculated T-scores between the 2 different types of x-ray exams?
Gender:
ALL
Ages:
20 years and above
Trial Updated:
02/12/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Healthy, Indicated for EOSedge Imaging
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
Recruiting
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Recruiting
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
02/12/2025
Locations: Belite Study Site, Warrenton, Virginia
Conditions: Geographic Atrophy
Left vs Left Randomized Clinical Trial
Recruiting
The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
Recruiting
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
02/12/2025
Locations: Eastern Virginia Medical School, Norfolk, Virginia
Conditions: Sleep Apnea, Obstructive
Evolut™ EXPAND TAVR II Pivotal Trial
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/12/2025
Locations: Carilion Roanoke Memorial Hospital, Roanoke, Virginia
Conditions: Moderate Aortic Valve Stenosis
Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures
Recruiting
The incidence of moderate to severe congenital heart disease (CHD) in the United States is estimated to be 6 per 1000 live-born full term infants. Recent advances in pediatric cardiology, surgery and critical care have significantly improved the survival rates of patients with CHD leading to an increase in prevalence in both children and adults. Children with CHD significant enough to require cardiac surgery frequently also undergo non-cardiac surgical procedures. Analysis of the Pediatric Healt... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/12/2025
Locations: Children's Hospital of the King's Daughter, Norfolk, Virginia
Conditions: Congenital Heart Disease in Children